title: [New targets in type 2 diabetes therapy].
abstract: The growing number of patients with type 2 diabetes stimulates the development of new antidiabetic drugs. New targets are addressed, as SGLT2 in the kidney or enzymes of glucose metabolism in the liver which might help to lower glucose levels and to overcome insulin resistance. The forthcoming years will show which of the drugs in clinical trials will get marketing authorization.
authors.affiliation: medizinjournalistin@gmx.net
authors.forename: Iris
authors.initials: I
authors.lastname: Hinneburg
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007333:Insulin Resistance; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects; D056564:Sirtuin 1 / Q000187:drug effects; D051297:Sodium-Glucose Transporter 2 / Q000187:drug effects
chemical_list: D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; C040985:phosphatidylinositol receptors; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D017853:Phosphotransferases (Alcohol Group Acceptor); C046331:phosphoglucokinase; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D005947:Glucose